HomeAI · summaries
Storia in 3 fonti
Broker’s call: Dr Reddy’s Lab (Accumulate)
Dr Reddy’s Labs faces temporary setbacks with Semaglutide; maintain Accumulate rating, target price ₹1,400 amid potential risks.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
economictimes.indiatimes.com
Dr Reddy's flags quality issue in semaglutide batches, delays commercial supplies
Dr Reddy's Laboratories has announced a setback in the distribution of their semaglutide products attributed to out-of-specification batches associated with an active ingredient…
- ·
thehindubusinessline.com
Dr Reddy's delays semaglutide supply due to active ingredient issue
Dr. Reddy's delays semaglutide supply due to ingredient issues, impacting shares but posing no safety risks.
